Why the study?
Do standard therapeutic doses of enoxaparin increase the risk of major bleeding in non-dialysis-dependent patients with severe renal insufficiency?
Do standard therapeutic doses of enoxaparin increase the risk of major bleeding in non-dialysis-dependent patients with severe renal insufficiency?
Standard therapeutic doses of enoxaparin in patients with severe renal insufficiency increase the risk of major bleeding, highlighting the potential need for empirical dose adjustment.
Answers are grounded in this paper and cite their sources.
Supports empirical enoxaparin dose adjustment in CrCl ≤30 mL/min; confirms elevated major bleeding risk via meta-analysis.
Non-dialysis-dependent patients with a creatinine clearance of 30 mL/min or less who are treated with standard therapeutic doses of enoxaparin have elevated levels of anti-Xa and an increased risk for major bleeding. Empirical dose adjustment of enoxaparin may reduce the risk for bleeding and merits additional evaluation. No conclusions can be made regarding other LMWHs.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: